IL1A and type 2 diabetes mellitus: Importantly, blockade of IL‐1 signalling in patients with type 2 diabetes with recombinant human IL‐1Ra (Anakinra) has also been shown to improve glycaemic control and β‐cell function and reduced markers of systemic inflammation.13